AI Slashes Time and Costs in Late-Stage Cancer Trials, Tufts Finds

Tufts’ Center for the Study of Drug Development finds Medable’s AI monitoring agent can speed up late-stage (phase 2/3) cancer drug trials by about 10 weeks and cut direct operating costs by up to $5.6 million, with larger net benefits as the drug targets more cancers (potentially up to $565 million for 50 indications). The technology could become standard in 3–5 years, aiding enrollment, data locking, and earlier safety assessments, while still facing challenges like patient recruitment, consent, drug distribution, and the need for human verification.